K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine

Antiviral Therapy

Volumn 8, Issue 2, 2003, Pages 173-182

  Røge, Birgit T ^a   Katzenstein, Terese L ^a   Obel, Niels ^b   Nielsen, Henrik ^c   Kirk, Ole ^d   Pedersen, Court ^b   Mathiesen, Lars ^d   Lundgren, Jens ^d   Gerstoft, Jan ^a  

^a Rigshospitalet   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DENMARK; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; STAVUDINE; TIME FACTORS; TREATMENT FAILURE;

EID: 0038369024     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT, Romero C, Kelleher D, Spreen W & LaFon S. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998; 12:F203-F209.
2. Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE & Pearce G. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12:F197-F202.
3. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H & Spreen W. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. Journal of the American Medical Association 2001; 285:1155-1163.
4. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R & Moore S. Simplification with abacavirbased triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15:1517-1526.
5. Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q & Shaefer MS. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. Journal of Infectious Diseases 2001; 183:571-578.
6. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society USA Panel. Journal of the American Medical Association 2002; 288:222-235.
7. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M & Larder B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Journal of Infectious Diseases 2000; 181:912-920.
8. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.
9. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
10. Walter H, Schmidt B, Werwein M, Schwingel E & Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrobial Agents & Chemotherapy 2002; 46:89-94.
11. Jorgensen LB, Katzenstein TL, Gerstoft J, Mathiesen LR, Pedersen C & Nielsen C. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine. Antiviral Therapy 2000; 5:187-194.
12. Khanna N, Klimkait T, Schiffer V, Irigoyen J, Telenti A, Hirschel B & Battegay M. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. AIDS 2000; 14:791-799.
13. Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M & LaFon S. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1infected adults with no prior antiretroviral therapy. Antiviral Therapy 2002; 7:43-51.
14. Bloor S, Kemp SD, Hertogs K, Alcorn T & Larder BA. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 1200 samples from the USA in 1999. Antiviral Therapy 2000; 5(Suppl. 3). Abstract 169.
15. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, & Purdon S. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 2000; 14:781-789.
16. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J & Fantini J. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. Journal of Clinical Microbiology 1999; 37:4099-4106.
17. Coakley EP, Gillis JM & Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-F15.
18. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H & Segondy M. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 1999; 13:1705-1709.
19. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, Ferchal F & Molina JM. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. Journal of Infectious Diseases 2001; 184:781-784.
20. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den EC, Van GV, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B & Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy 1998; 42:269-276.
21. Lacey SF & Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents & Chemotherapy 1994; 38:1428-1432.
22. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T & Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrobial Agents & Chemotherapy 1997; 41:757-762.
23. Ait-Khaled M, Lanier R, Richards N, Stone C, Griffin P, Gibb DM, Walker AS, Craig C, Loeliger AE & Tisdale M. Zidovudine appears to prevent selection of K65R and L74V mutations normally selected by abacavir mono- or combination therapies not containing zidovudine. Antiviral Therapy 2002; 7(Suppl. 1). Abstract 129.
24. Huang H, Chopra R, Verdine GL & Harrison SC. Structure of a covalently trapped catalytic complex of HIV1 reverse transcriptase: implications for drug resistance. Science 1998; 282:1669-1675.
25. Gu Z, Gao Q, Fang H, Parniak MA, Brenner BG & Wainberg MA. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994; 8(Suppl. 1):S166-S169.
26. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD & Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrobial Agents & Chemotherapy 2002; 46:3437-3446.
27. Gu Z, Arts EJ, Parniak MA & Wainberg MA. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′triphosphate and other drugs. Proceeding of the National Academy of Sciences, USA 1995; 92:2760-2764.
28. Sluis-Cremer N, Arion D, Kaushik N, Lim H & Parniak MA. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochemical Journal 2000; 348:77-82.
29. Shah FS, Curr KA, Hamburgh ME, Parniak M, Mitsuya H, Arnez JG & Prasad VR. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 2000; 275:27037-27044.
30. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH & Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. Journal of Virology 2000; 74:9339-9346.
31. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
32. Miller M, Coakley D, Cheng A, Margot N, Tran S & McColl D. Genotypic and phenotypic characterization of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). 6th International Congress on Drug Therapy in HIV Infection; 17-21 November 2002, Glasgow, UK. Abstract P205.
33. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33:1931-1937.
34. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
35. Mokrzycki MH, Harris C, May H, Laut J & Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clinical Infectious Diseases 2000; 30:198-200.